1. Considered and approved the Audited Financial Results for the fourth quarter and Financial Year Ended 31st March, 2025. The said Audited Financial Results were reviewed by the Audit ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical's board approved audited financial results for Q4 and FY ended March 31, 2025, along with shifting of its corporate office within Hyderabad (from Gachibowli to Kukatpally). Revenue from operations jumped nearly threefold to Rs 10,929.86 lakhs in FY25 from Rs 3,964.21 lakhs in FY24, a growth of about 175%. However, the net loss widened sharply to Rs 1,029.83 lakhs versus Rs 347.93 lakhs in the previous year. Q4 FY25 also posted a loss of Rs 215.29 lakhs. The statutory auditor (A.M Reddy & D.R Reddy) issued an unmodified (clean) opinion on the results. The company reported negative other equity of Rs 6,262.40 lakhs, indicating eroded net worth, and total borrowings of Rs 6,223.24 lakhs.
Strong revenue growth is a positive, but deepening losses and negative net worth raise concerns about the company's financial health and sustainability. Shareholders should watch whether the topline growth translates into profitability going forward; near-term stock reaction may be cautious given the widened losses and weak balance sheet despite the clean auditor opinion.